Company
Kalexo Bio
Driving the Next Generation of Cardiovascular Risk Reduction
Also known as Kalexo Bio, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2025
- Legal name
- Kalexo Bio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Kalexo Bio is advancing dual-targeting siRNA therapeutics to address the most critical unmet needs in cardiovascular disease. By dual-targeting the key genetic drivers of cardiovascular disease, our approach is designed to deliver potent, durable risk reduction—starting with lipid management and atherosclerotic disease prevention. Our lead program has the potential to redefine the standard of care.
Loading relationship preview